Zhen Li,Rui Zhu,Christine I. Wooddell,Bruce D. Given,Tao Pei,David L. Lewis,Lauren J. Almeida,David B. Rozema,Darren H. Wakefield
申请号：
US16267194
公开号：
US20190255091A1
申请日:
2019.02.04
申请国别(地区):
US
年份:
2019
代理人:
摘要：
Described are compositions and methods for inhibition of Hepatitis B virus gene expression. RNA interference (RNAi) agents for inhibiting the expression of Hepatitis B virus gene are described. The HBV RNAi agents disclosed herein may be targeted to cells, such as hepatocytes, for example, by using conjugated targeting ligands. Pharmaceutical compositions comprising one or more HBV RNAi agents optionally with one or more additional therapeutics are also described. Delivery of the described HBV RNAi agents to infected liver in vivo provides for inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.
